---
title: "Roche invites investors and analysts to virtual ADA Investor Event; Phase II obesity data at ADA"
sdDatePublished: "2026-05-07T10:06:00Z"
source: "https://www.roche.com/investors/updates/inv-update-2026-05-07b"
topics:
  - name: "health"
    identifier: "medtop:07000000"
  - name: "science and technology"
    identifier: "medtop:13000000"
  - name: "economy, business and finance"
    identifier: "medtop:04000000"
  - name: "human interest"
    identifier: "medtop:08000000"
  - name: "pharmaceutical"
    identifier: "medtop:20000223"
locations:
  - "Switzerland"
  - "United States"
---


Roche invites investors and analysts to virtual ADA Investor Event; Phase II obesity data at ADA

Invitation to Roche’s Virtual ADA Investor Event

skip to content Stories Careers Contact About Roche About Roche Business Governance Sustainability Roche Global Citizenship Strategy Leadership History Solutions Solutions Focus areas Pharma solutions Diagnostic solutions Product Development Pipeline Innovation Innovation Partnering Ethical standards Team and structure Innovation process Clinical trials Investors Investors Investor updates Investor events Reporting Finance Information Tool Share and Bond information Download center Frequently asked questions Media Media Media releases Media events Media statements Media library About Roche About Roche Business Business Diagnostics Pharma Governance Governance Annual general meetings Board of directors Committees Executive committee Code of conduct Sustainability Sustainability Approach Goals and performance ESG index Safety health and wellbeing Roche Global Citizenship Roche Global Citizenship Arts and culture Community disaster relief Humanitarian social development React Rebuiding communities Science and education Strategy Leadership History Solutions Solutions Focus areas Focus areas Cardiometabolic Haematology Diabetes Immunology Infectious diseases Inflammatory bowel diseases Neurology Oncology Ophthalmology Respiratory Women's health Pharma solutions Pharma solutions Safety reporting Diagnostic solutions Diagnostic solutions Safety officers Product Development Pipeline Innovation Innovation Partnering Partnering Pharma Diagnostics Areas of interest Ethical standards Ethical standards Advisory Animal research Genetics Team and structure Team and structure R&D locations Innovation process Clinical trials Investors Investors Investor updates Investor events Reporting Finance Information Tool Share and Bond information Download center Frequently asked questions Media Media Media releases Media events Media statements Media library Stories Careers Contact worldwide Investors Investor updates Invitation to Roche’s Virtual ADA Investor Event 2026-05-07 We are pleased to invite investors and analysts to participate in our virtual event on Monday, 8 June 2026 , to highlight the new data from the Phase II 103 study of enicepatide in obesity, as well as from the Phase II ZUPREME-1 study of petrelintide in obesity, which will be presented at the American Diabetes Association’s (ADA) Scientific Sessions from 05-08 June 2026. 17:00-18:30 CEST

11:00-12:30 EDT Agenda Introduction Bruno Eschli, Head of Investor Relations Roche obesity strategy Morten Lammert, Global Therapeutic Area Head Cardiovascular, Renal & Metabolism Obesity pipeline overview Manu Chakravarthy, SVP, Global Head of Product Development Cardiovascular, Renal & Metabolism Enicepatide Ph II (103) results in obesity Ildiko Lingvay, MD, MPH, MSCS; Tenured Professor of Medicine in Endocrinology; External consultant to Roche and Genentech Petrelintide Ph II (ZUPREME-1) results in obesity Louis J. Aronne, MD; Past-President of the Obesity Society, Founder and Chair Emeritus of the American Board of Obesity Medicine and Endowed Professor of Metabolic Research; External consultant to Roche and Genentech Q&A The slides will be available for download at 16:00 CEST on the day of the event. > click here Access to virtual event (pre-registration required) Please pre-register for our webinar here*. Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com . A replay of the webcast will be available via > ir.roche.com * privacy notice Best regards, Bruno Eschli Head of Investor Relations Jan-Philipp Schwarzhans Investor Relations Officer Roche Investor Relations Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com Investor Relations North America Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com Helpful links Reporting Pipeline Finance information tool Ad hoc announcements Events Services Investor Relations team Send e-mail Subscribe to Roche Investor updates print or save as pdf Investors Investor updates view all stay updated get the latest news and updates to your inbox. subscribe